Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Summary

To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

Timeline

Start

2023-08-12

Primary completion

2024-09-24

Completion

2024-09-24

Drugs

Indications